MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space
MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space
MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space
MIP Discovery achieves Silver LEAF lab status in its path to sustainable science MIP Discovery is proud to share that the business has received Silver status in the Laboratory Efficiency Assessment Framework (LEAF), demonstrating the business’s continued commitment to environmental sustainability.
MIP Discovery announces drugs of abuse reagent launch Novel nanoMIPTM affinity reagents engineered to recognise metabolites of the synthetic opioid, fentanyl are now available for research evaluation. It is hoped that these reagents will help combat the growing wave of deaths in North America attributable to synthetic opioids.
MIP Discovery secures significant funding to support development of global rapid response diagnostics Funding received from the Bill & Melinda Gates Foundation for rapid deployment of novel detection reagents to support mass scale testing in low to middle-income countries
MIP Discovery Adopts the Fida 1 Platform Funding received from the Bill & Melinda Gates Foundation for rapid deployment of novel detection reagents to support mass scale testing in low to middle-income countries
Stay up to date with the latest news from MIP Discovery
Our website uses cookies to provide you the best experience. However, by continuing to use our website, you agree to our use of cookies. For more information, read our Cookie Policy.